Page last updated: 2024-08-26

beta-carboline-3-carboxylic acid ethyl ester and zaprinast

beta-carboline-3-carboxylic acid ethyl ester has been researched along with zaprinast in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Coste, H; Daugan, A; Grondin, P; Hyafil, F; Kirilovsky, J; Labaudinière, R; Le Monnier de Gouville, AC; Ruault, C1
Leeson, PD; Young, RJ1

Reviews

1 review(s) available for beta-carboline-3-carboxylic acid ethyl ester and zaprinast

ArticleYear
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.
    Journal of medicinal chemistry, 2018, 08-09, Volume: 61, Issue:15

    Topics: Animals; Chemical Phenomena; Drug Discovery; Humans; Hydrophobic and Hydrophilic Interactions

2018

Other Studies

1 other study(ies) available for beta-carboline-3-carboxylic acid ethyl ester and zaprinast

ArticleYear
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
    Journal of medicinal chemistry, 2003, Oct-09, Volume: 46, Issue:21

    Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Pressure; Carbolines; Cattle; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Hydantoins; Indicators and Reagents; Isomerism; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Rats; Rats, Inbred SHR; Structure-Activity Relationship; Tadalafil

2003